Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
NCT03894215 · View on ClinicalTrials.gov ↗
Study Summary
This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2- combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy. The study is not intended to compare the efficacy of the 2 experimental arms. Rather, the efficacy of each arm will be evaluated against its relevant historical controls as appropriate.
Conditions Studied
Interventions
- DRUG AGEN2034
- DRUG AGEN1884
Study Locations (20)
California
- University of California, San Diego (UCSD) - Moores Cancer Center — La Jolla
- UCLA- Women's Health Clinical Research Unit (WHCRU) — Los Angeles
- Gynecologic Oncology Associates — Newport
- California Pacific Medical Center — San Francisco
- University of California, San Francisco Medical Center — San Francisco
Alabama
- University of Alabama at Birmingham School of Medicine — Birmingham
- University of South Alabama Mitchell Cancer Institute — Mobile
Arizona
- Arizona Oncology - Biltmore Cancer Center — Phoenix
- Arizona Oncology - Tucson - Wilmot Road Location — Tucson
Florida
- Baptist MD Anderson Cancer Center — Jacksonville
- Moffitt Cancer Center — Tampa
Georgia
- Northside Hospital — Atlanta
- St Joseph's Hospital — Savannah
New York
- Northwell Health Monter Cancer Center — Lake Success
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York
Indiana
- Community Health Network - North Cancer Center — Indianapolis
Kentucky
- University of Kentucky Albert B. Chandler Hospital — Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2019-06-01 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03894215
The ClinicalTrials.gov registry entry for NCT03894215 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 8 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions — of which AGEN2034 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03894215 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Alabama, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03894215 about?
NCT03894215 is a clinical study titled "RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer". This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2- combination therapy) for treatment of patients with advanced cervical cancer who r...
What is the current status of trial NCT03894215?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2019-06-01. Estimated completion is 2026-09.
What conditions does trial NCT03894215 study?
This clinical trial studies the following conditions: Cervical Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03894215?
The interventions under investigation include: AGEN2034 (DRUG), AGEN1884 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03894215?
This trial is sponsored by Agenus, which has 8 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03894215 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.